TWI614031B - 防止皮膚老化相關症狀的醫藥組合物及其使用方法 - Google Patents
防止皮膚老化相關症狀的醫藥組合物及其使用方法 Download PDFInfo
- Publication number
- TWI614031B TWI614031B TW101140641A TW101140641A TWI614031B TW I614031 B TWI614031 B TW I614031B TW 101140641 A TW101140641 A TW 101140641A TW 101140641 A TW101140641 A TW 101140641A TW I614031 B TWI614031 B TW I614031B
- Authority
- TW
- Taiwan
- Prior art keywords
- vector
- cisd2
- item
- skin
- gene
- Prior art date
Links
- 230000009759 skin aging Effects 0.000 title claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title abstract description 17
- 101150026325 CISD2 gene Proteins 0.000 claims abstract description 48
- 239000013598 vector Substances 0.000 claims abstract description 47
- 208000024891 symptom Diseases 0.000 claims abstract description 30
- 101000989662 Homo sapiens CDGSH iron-sulfur domain-containing protein 2 Proteins 0.000 claims abstract description 17
- 102100029348 CDGSH iron-sulfur domain-containing protein 2 Human genes 0.000 claims abstract description 14
- 210000003491 skin Anatomy 0.000 claims description 29
- 210000001732 sebaceous gland Anatomy 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 21
- 210000003780 hair follicle Anatomy 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 210000004209 hair Anatomy 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 241001529936 Murinae Species 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 210000002706 plastid Anatomy 0.000 claims description 5
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 230000002500 effect on skin Effects 0.000 claims description 4
- 210000004761 scalp Anatomy 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 241000709664 Picornaviridae Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 210000002615 epidermis Anatomy 0.000 claims description 3
- 102000055885 human CISD2 Human genes 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 208000005623 Carcinogenesis Diseases 0.000 claims description 2
- 101100383897 Homo sapiens CISD2 gene Proteins 0.000 claims description 2
- 230000036952 cancer formation Effects 0.000 claims description 2
- 231100000504 carcinogenesis Toxicity 0.000 claims description 2
- 230000005779 cell damage Effects 0.000 claims description 2
- 208000037887 cell injury Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 241000699660 Mus musculus Species 0.000 description 15
- 238000011830 transgenic mouse model Methods 0.000 description 13
- 230000032683 aging Effects 0.000 description 12
- 230000009261 transgenic effect Effects 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 230000003660 hair regeneration Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012637 gene transfection Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 101150060709 CISD1 gene Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 102100038817 CDGSH iron-sulfur domain-containing protein 1 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical compound [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000883055 Homo sapiens CDGSH iron-sulfur domain-containing protein 1 Proteins 0.000 description 1
- 102000005298 Iron-Sulfur Proteins Human genes 0.000 description 1
- 108010081409 Iron-Sulfur Proteins Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100383899 Mus musculus Cisd2 gene Proteins 0.000 description 1
- 101100383903 Mus musculus Cisd3 gene Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000001406 Perilipin Human genes 0.000 description 1
- 108060006002 Perilipin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000021125 mitochondrion degradation Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 230000037316 sun-exposed skin Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本發明提供一種醫藥組合物，其透過表現Cisd2基因來防止皮膚老化相關症狀；並提供一種防止皮膚老化相關症狀的方法，其包含投予一攜帶Cisd2基因之載體；此外，本發明進一步提供另外一種防止皮膚老化相關症狀的醫藥組合物，其包含一CISD2蛋白。
Description
本發明係關於一種防止皮膚老化相關症狀的醫藥組合物及其使用方法。
造成皮膚的老化原因可區分為外在的與內在的因素，內在的因素包含先天基因隨時間排程的老化，影響到陽光曝曬及非曝曬的皮膚，特徵為皮膚變的乾燥、鬆弛、出現皺紋及萎縮。基因上的老化因人而異，所以皮膚隨老化而失去的緊實感及彈性會因個人而有所不同，而且同一個人身上的皮膚也會因不同的部位而有不同程度的老化。
外在的因素主要是由於環境中界所接觸的有害因子，如抽煙、污染物質及陽光。慢性反覆性的曝露於陽光(紫外線A及B)是造成皮膚老化最顯著的外在因子，這種老化又稱之為日光性老化。日光性老化影響部位為曝曬於陽光的皮膚，臨床特徵為皮膚出現細小及粗大皺紋、表面粗糙、乾燥、鬆弛、細小微血管擴張、紫斑以及出現不規則的色素沉澱，如黑斑(老年斑或肝斑)及去色素斑，同時罹患良性及惡性皮膚癌的機率也會增加。
皮膚抗老化一直是生物科技研究重要的課題與目標，在目前皮膚抗老化的避免上面，並無任何有效機制或藥物可以減緩或停止先天性基因的自然老化，因此，目前在臨床上僅能消極的透過預防接觸外在因素的有害分子以減緩皮膚老化過程。
目前於市場上或研究上，有許多研發藥物或機器已被用來改善人體防止接觸外在因素的有害分子以減緩皮膚老化，包括外用抗氧化物如維他命C及E、大豆異黃胴素、茶葉多酚等，使用保溼劑，維他命A酸，果酸等；使用皮膚美白產品如左旋維他命C及麴酸等，注射肉毒桿菌素，玻尿酸或膠原蛋白，也可使用雷射或脈衝光換膚甚至電波拉皮等。
發明人先前的研究中發現，Cisd2基因所表現的蛋白，在細胞內主要位在粒線體的外膜上面。粒線體則是一個含雙層膜(外膜和內膜)的胞器，是細胞製造能量的工廠，當缺少Cisd2蛋白時，在神經退化、肌肉萎縮之前，約在小鼠2週左右(約人類5至8歲)，粒線體的外膜首先出現破損，繼而內膜破損及整個粒線體破壞；粒線體的功能，例如進行有氧呼吸的電子傳遞鏈反應，也相繼受到影響；這些結果顯示Cisd2蛋白是維持粒線體結構完整的關鍵。由於粒線體是細胞製造能量的工廠，對肌肉和神經細胞尤其重要，一旦缺少Cisd2蛋白時，細胞能量的主要供應分子-三磷酸腺苷(ATP)即出現供應不足之失調情形，神經和肌肉首先受到影響，老鼠的老化徵狀因此接踵而來。
Cisd2基因屬於含有CDGSH硫鐵區域(CDGSH iron sulfur domain)家族，此家族基因之CDGSH為一保守區域(conserved domain)，此家族成員包含Cisd1基因、Cisd2基因及Cisd3基因。其中Cisd1會產生CISD1蛋白，此蛋白係為一穿膜蛋白；Cisd3對於第二型糖尿病有關。
Cids2基因位於染色體4q上，會產生CISD2蛋白，並參與在細胞死亡過程。過去研究顯示，缺乏Cisd2基
因的小鼠，其會有早熟、粒線體退化及失能的現象。
有鑑於此，發明人投入相當之心力，探就透過Cisd2基因的調控確認Cisd2基因在皮膚老化症狀是否扮演重要的角色，並研究如何透過調控Cisd2基因及CISD2蛋白的表現來防止皮膚老化症狀，本發明之技術將可成功提供一解決皮膚老化內在因素的方法，對於透過先天基因的調控來解決皮膚抗老化的研究領域提供一個重要的里程碑。
有鑑於此，本發明主要目的之一為在由基因層面提供一種透過增加Cisd2基因表現防止皮膚老化症狀的醫藥組合物及其使用方法，甚而提供一種檢測皮膚老化症狀的方法。
為達上述目的，本發明提供一種醫藥組合物，其係透過表現Cisd2基因來防止皮膚老化症狀。前述防止皮膚老化相關症狀的醫藥組合物，其包含一攜帶Cisd2基因之載體及一藥物上可接受之佐劑。
本發明又提供一種防止皮膚老化相關症狀的方法，其包含投予一攜帶Cisd2基因之載體。
較佳地，其中前述Cisd2基因係為一人類Cisd2基因或一鼠類Cisd2基因。
本發明再提供另外一種防止皮膚老化相關症狀的醫藥組合物，其包含一CISD2蛋白及一藥物上可接受之佐劑。
較佳地，佐劑係為無機佐劑、有機佐劑、合成佐劑或油劑。
較佳地，前述CISD2蛋白係為一人類CISD2蛋白或一鼠類CISD2蛋白。
較佳地，前述載體係為一傳染媒介載體(vector)、一脂質體(liposome)、一聚合物(polymer)、一醫藥可接受之組合物或一可便於攜帶之裝置。
較佳地，前述載體係為一腺病毒載體(adenovirus vector)、反轉錄病毒載體(retrovirus vector)、腺伴隨病毒載體(adeno-associated virus vector)、單純泡疹病毒載體(herpes simplex virus vector)、SV40載體、多瘤病毒載體(polyma virus vector)、乳突病毒載體(papilloma virus vector)、微小核糖核酸病毒載體(Picornavirus vector)、疫苗病毒載體(vaccinia virus vector)、慢病毒載體(lentiviral vector)、α-病毒載體、輔助病毒依賴型腺病毒載體(helper-dependent adenovirus vector)或一質體。
較佳地，前述皮膚老化相關症狀係為細胞損傷、組織損傷、器官失能、皮膚老化相關壽命減少或致癌作用(carcinogenesis)。
較佳地，前述組織包含皮膚組織或脂肪組織，其中皮膚組織包括表皮層、真皮層、脂肪層、毛囊、毛髮以及皮脂腺，而脂肪組織則包括脂肪層。
較佳地，前述皮膚老化相關症狀係為毛囊的減少、皮脂腺減少、皮脂腺細胞核減少、抗水性變弱、皮下脂肪層變薄、毛髮較無光澤、毛髮減少或或灰白毛髮較多。
較佳地，前述投予係透過塗抹於皮膚或頭皮上、體內注射、口服(oral administration)或上述方式之結合。其中上述體內注射又包含下列各種方法：靜脈內注射
(intravenous administration)、皮下注射(subcutaneous administration)、動脈內注射(intra-arterial administration)、肌肉內注射(intra-muscular administration)。
綜上所述，本發明提供二種醫藥組合物及其使用方法，可從Cisd2基因層面調控或利用其蛋白質，進而防止皮膚老化之相關症狀產生。進一步，可應用本發明技術進行皮膚老化症狀的檢測。
本發明所開發之醫藥組合物及其使用方法係透過表現Cisd2基因來防止皮膚老化症狀。前述防止皮膚老化相關症狀的醫藥組合物，其包含一攜帶Cisd2基因之載體。
本發明所述之Cisd2基因係為任何動物之Cisd2基因，於較佳實施例中，其為一人類Cisd2基因或一鼠類Cisd2基因。於較佳實施例中，其Cisd2基因序列係為：SEQ ID NO：1。
本發明所述之CISD2蛋白任何動物之CISD2蛋白，於較佳實施例中，其為一人類CISD2蛋白或一鼠類CISD2蛋白。於較佳實施例中，其CISD2蛋白之胺基酸序列係為：SEQ ID NO：2。
本發明所述「佐劑」係為無機佐劑、有機佐劑、合成佐劑或油劑。包含，但不限於：氫氧化鋁、明礬、微生物、雙股多核苷酸鏈、異丙肌苷、礦物油或花生油等。
本發明所述之「載體」係指任何可便於傳輸之物品，包含，但不限於：為一傳染媒介載體(vector)、一
脂質體(liposome)、一聚合物(polymer)、一醫藥可接受之組合物或一可便於攜帶之裝置。在較佳實施例中，前述載體係為一腺病毒載體(adenovirus vector)、反轉錄病毒載體(retrovirus vector)、腺伴隨病毒載體(adeno-associated virus vector)、單純泡疹病毒載體(herpes simplex virus vector)、SV40載體、多瘤病毒載體(polyma virus vector)、乳突病毒載體(papilloma virus vector)、微小核糖核酸病毒載體(Picornavirus vector)、疫苗病毒載體(vaccinia virus vector)、慢病毒載體(lentiviral vector)、α-病毒載體、輔助病毒依賴型腺病毒載體(helper-dependent adenovirus vector)或一質體。
本發明所述之「皮膚老化相關症狀」係指習知之皮膚老化症狀，包括，但不限於：毛囊的減少、皮脂腺減少、皮脂腺細胞核減少、抗水性變弱、皮下脂肪層變薄、毛髮較無光澤、毛髮減少或灰白毛髮較多。
本發明所「適用之組織」包含各種動物組織，包含，但不限於：皮膚組織或脂肪組織。
本發明所述之「投予方式」可為各種將醫藥組合物傳輸至身體的方式，包含，但不限於：塗抹於皮膚或頭皮上、體內注射、口服(oral administration)或上述方式之結合。其中上述體內注射又包含下列各種方法：靜脈內注射(intravenous administration)、皮下注射(subcutaneous administration)、動脈內注射(intra-arterial administration)、肌肉內注射(intra-muscular administration)。
以下實施例僅為本發明之示例性實施，目的在於闡述本發明詳細實施方式，不在於限制本發明範疇，並且針對本發明實施例使用的實驗操作方式作詳細說明。
收集各種小鼠組織，用含磷酸之10%福爾馬林緩衝液固定，再用石蠟包埋。組織切片(3-4微米)進行蘇木精-伊紅(Hematoxylin-Eosin,H&E)和Masson三色(tirchome)染色(參照：Young and Health,2003)。
將石蠟包埋的骨骼肌(3微米)進行圍脂滴蛋白perilipin的免疫組織染色。先將骨骼肌切片浸泡在含有10mM檸檬酸鈉的抗原修復緩衝液(pH值6.0)中，在微波爐(尚朋堂SM-1220，650W)中加熱10分鐘共2次。然後將切片與原發性抗圍脂滴蛋白(perilipin)抗體(1：100，Cell signaling D418的兔來源多株抗體)培養在25-40℃環境下18~24小時，並以次級抗體(Invitrogen Flour，共軛山羊抗兔抗體)偵測之。再將切片用螢光顯微鏡(OLYPUS BX51)拍攝圖片(搭配軟體：DP Controller Ver.3.1.1.267)。其中細胞核以DAPI(4'-6-二脒基-2-苯基吲哚，Sigma公司)染色並計量。
將各種小鼠組織以含有戊二醛(1.5%)和多聚甲醛(1.5%)的磷酸鹽緩衝混合液(pH7.3)固定。再以1% OsO4及1.5%的hexanoferrate鉀(potassium hexanoferrate)溶液進行後固定，然後以二甲砷酸(cacodylate)和0.2 M5的馬來酸鈉緩衝液(pH值6.0)潤洗，再以1%乙酸雙氧鈾進行塊狀染色。接著進行脫水，各種組織被EPON
包覆並切片，再如前述以TEM觀察之(參考Kao et al,1995)。
將結果以平均值±SD表示，並使用Student’s t test檢驗比較兩個組的數據。當分析不同組的統計數據時，P<0.05被判定是有顯著差異的。
本說明書所載CISD2轉基因質體的構成如下：具體來說，鼠的CISD2蛋白生成基因是由RNA-5-聚合酶II之大次單元啟動子來驅動(Pol II；NCBI Accession M14101 bases 1-712)。pIRES-EGFP質體(CLONTECH #6064-1)衍生出0.33 kb的合成內含子和0.28 kb的牛生長激素polyA信號(PA)。兩個重複的“HS4雞肉的絕緣體(NCBI Accession U78775 bases 10-1199)被插於polyA信號之下游以阻止位置效應(positional effects)。將C57BL/6受精卵以原核顯微注射，以產生10隻CISD2基因轉殖鼠。以PCR測定前述鼠尾部DNA的表現型。小鼠被飼養在無特定病原體的環境下。這項動物實驗流程係由陽明大學的「實驗動物照護和使用委員會」所製定。
為了確認Cisd2基因對皮膚(毛髮)老化症狀的影響，以15個月大之未經基因轉殖鼠(15-mo WT)及34個月大之經基因轉殖鼠(34-mo TG)進行外觀比較，其
結果如第一圖所示。由外觀看來，經Cisd2基因轉殖鼠其有延緩色素沉澱(delayed de-pigmentation)的現象，且相較於較為年幼之未經基因轉殖鼠，其毛髮較不灰白。
接著，以3個月大之未經基因轉殖鼠(野生型)及24個月大之經基因轉殖鼠(基因轉殖型)之毛囊進行梅生三色染色(Masson’s trichome staining)再進行比較，其結果如第二圖所示。
其中，HF代表毛囊(hair follicles)，SG代表皮脂腺(sebaceous gland)。
將上述結果量化，其結果如第三圖所示，其中，第三A圖代表每個毛囊中皮脂腺之細胞核數目，第三B圖代表每個毛囊之皮脂腺數目。
皮脂腺係毛囊中分泌皮脂的組織。比較3個月大之未經基因轉殖鼠(野生型)及24個月大之經基因轉殖鼠(基因轉殖型)，由上述實驗結果可知，當轉殖了Cisd2基因後，鼠毛囊之皮膚老化相關的萎縮症狀就減少了，且含有二個皮脂腺的毛囊也顯著地增加了。
皮脂腺會分泌皮脂以包覆於毛囊外，在有毛的哺乳類動物中，這些皮脂對於動物抗水性及溫度調節扮演重要的角色。此外，不同年齡的動物之皮脂腺分泌能力不同，對水的抗性也不同。
為了觀察Cids2基因轉殖後，對鼠之抗水性及溫度
調節能力的影響，取3個月大之未經基因轉殖鼠(野生型)及24個月大之經基因轉殖鼠(基因轉殖型)進行抗水試驗(water repulsion)的比較。每一組有4隻小鼠。
將試驗對象鼠浸入37℃的水中3分鐘，再將之取出，置於紙毛巾上以吸去多餘水分，測量5~60分鐘之體重和體溫，其結果如第四圖所示。
結果顯示，鼠被浸入水中再取出5分鐘後，無論有無經過基因轉殖，3個月大的鼠皆已幾乎全乾。相較於此，24個月大之未經基因轉殖鼠(野生型)，其對水的抗性較差。再看24個月大之基因轉殖鼠(基因轉殖型)，其對水的抗性則與3個月大的鼠相近。由此可知，經過Cisd2基因轉殖後，會使鼠的抗水性能力提升。
皮膚的皮膚老化與皮膚厚度減少有關，主要因為皮下脂肪及肌肉的減少。因此接著以組織染色觀察試驗鼠之皮膚厚度，包含真皮層、脂肪層和肌肉層的厚度，其結果如第五圖所示。接著，量化前述結果，如第六圖所示，第六A圖為皮膚(包括真皮層、脂肪層、肌肉層)厚度，第六B圖為真皮層厚度，第六C圖為脂肪層厚度。
在第五圖及第六圖中可見，24個月大之試驗鼠皮膚組織中，經Cisd2基因轉殖(基因轉殖型)的小鼠其皮膚(包括真皮層、脂肪層、肌肉層)厚度較未經基因轉殖(野生型)的小鼠要厚。
取12個月大的小鼠，分為二個族群，一為經基因轉殖(基因轉殖型)及一為未經基因轉殖(野生型)，觀察其毛髮再生現象，其結果如第七圖所示。
由圖可知，經過Cisd2基因轉殖的小鼠其毛髮再生
現象要比未經基因轉殖(野生型)的小鼠要來得顯著。
綜上所述，皮膚老化症狀包括：皮脂腺與毛囊的萎縮、掉髮、皮膚(包括真皮層、脂肪層、肌肉層)厚度變薄(因為皮下脂肪與肌肉的萎縮所導致)。本發明Cisd2基因轉殖可延緩因皮膚老化引起的皮脂腺與毛囊萎縮，由於皮脂腺未萎縮，因此可分泌適量油脂於皮膚表面(表皮層)，達到抗水的功效，使老鼠從浸溼到乾的時間也較短，更可增加「有結合2個皮脂腺的毛囊」之比例，使毛髮較具有光澤，也較少白頭髮，並增加頭髮再生的速率，顯著的防止皮膚老化症狀。
第一圖係為Cisd2基因轉殖前後之小鼠外觀比較圖。
第二圖係為Cisd2基因轉殖前後之小鼠的毛囊組織染色圖。
第三圖係為Cisd2基因轉殖前後之小鼠的毛囊組織中皮脂腺細胞核及皮脂腺數量的統計。
第四圖係為Cisd2基因轉殖前後之小鼠抗水性試驗結果。
第五圖係為Cisd2基因轉殖前後之小鼠之皮膚組織(真皮層、脂肪層、肌肉層)染色圖。
第六圖係為Cisd2基因轉殖前後之小鼠皮膚組織(真皮層、脂肪層、肌肉層)厚度的量化結果。
第七圖係為Cisd2基因轉殖前後之小鼠的毛髮再生現象圖。
<110> 國立陽明大學
<120> 防止皮膚老化相關症狀的醫藥組合物及其使用方法
<130> 2011RDPA013
<150> US61/555,182
<151> 2011-11-03
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 2885
<212> DNA
<213> Mus musculus
<400>1
<210> 2
<211> 135
<212> PRT
<213> Mus musculus
<400> 2
Claims (12)
- 一種用於製備防止皮膚老化相關症狀之醫藥組合物的用途，其中該組合物包含一攜帶Cisd2基因之載體以及一藥物上可接受之佐劑。
- 如申請專利範圍第1項所述之用途，其中前述Cisd2基因係為一人類Cisd2基因或一鼠類Cisd2基因。
- 如申請專利範圍第1項所述之用途，其中前述載體係為一傳染媒介載體(vector)、一脂質體(liposome)、一聚合物(polymer)、一醫藥可接受之組合物或一可便於攜帶之裝置。
- 如申請專利範圍第3項所述之用途，其中前述傳染媒介載體係為一腺病毒載體(adenovirus vector)、反轉錄病毒載體(retrovirus vector)、腺伴隨病毒載體(adeno-associated virus vector)、單純泡疹病毒載體(herpes simplex virus vector)、SV40載體、多瘤病毒載體(polyma virus vector)、乳突病毒載體(papilloma virus vector)、微小核糖核酸病毒載體(Picornavirus vector)、疫苗病毒載體(vaccinia virus vector)、慢病毒載體(lentiviral vector)、α-病毒載體、輔助病毒依賴型腺病毒載體(helper-dependent adenovirus vector)或一質體。
- 如申請專利範圍第1項所述之用途，其中前述皮膚老化相關症狀係為細胞損傷、組織損傷、器官失能、皮膚老化相關壽命減少或致癌作用(carcinogenesis)。
- 如申請專利範圍第5項所述之用途，其中前述組織係為一皮膚組織或一脂肪組織。
- 如申請專利範圍第6項所述之用途，其中該皮膚組織包括表皮層、真皮層、脂肪層、毛囊、毛髮及皮脂腺，該脂肪組織則包括脂肪層。
- 如申請專利範圍第1項所述之用途，其中前述皮膚老化相關症狀係為毛囊的 減少、皮脂腺減少、皮脂腺細胞核減少、抗水性變弱、皮下脂肪層變薄、毛髮較無光澤、毛髮減少或灰白毛髮較多。
- 如申請專利範圍第1項所述之用途，其中前述投予係透過注射於皮膚或頭皮上。
- 一種用於製備防止皮膚老化相關症狀之醫藥組合物的用途，其中該組合物包含一CISD2蛋白以及一藥物上可接受之佐劑。
- 如申請專利範圍第10項所述之用途，其中前述CISD2蛋白係為一人類CISD2蛋白或一鼠類CISD2蛋白。
- 如申請專利範圍第10項所述之用途，其中前述投予係透過注射於皮膚或頭皮上、體內注射、口服(oral administration)或上述方式之結合。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555182P | 2011-11-03 | 2011-11-03 | |
| US61/555,182 | 2011-11-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201322998A TW201322998A (zh) | 2013-06-16 |
| TWI614031B true TWI614031B (zh) | 2018-02-11 |
Family
ID=48280865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101140641A TWI614031B (zh) | 2011-11-03 | 2012-11-02 | 防止皮膚老化相關症狀的醫藥組合物及其使用方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20130122082A1 (zh) |
| CN (1) | CN103203027A (zh) |
| TW (1) | TWI614031B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101886342B1 (ko) * | 2010-11-30 | 2018-08-10 | (주)아모레퍼시픽 | 피부 노화와 관련된 유전자 및 피부 노화를 방지하는 물질을 스크리닝하는 방법 |
| CN117535350A (zh) * | 2016-05-20 | 2024-02-09 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
| JP2023524010A (ja) * | 2020-04-28 | 2023-06-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 高効率遺伝子送達系 |
| TWI831339B (zh) * | 2021-08-24 | 2024-02-01 | 國立陽明交通大學 | 化合物用於製備Ｃｉｓｄ２不足相關病症的藥物的用途 |
-
2012
- 2012-11-02 TW TW101140641A patent/TWI614031B/zh active
- 2012-11-02 CN CN2012104331288A patent/CN103203027A/zh active Pending
- 2012-11-03 US US13/668,268 patent/US20130122082A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Yi-Fan Chen et al., "Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice", GENES & DEVELOPMENT 23:1183–1194. * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201322998A (zh) | 2013-06-16 |
| US20130122082A1 (en) | 2013-05-16 |
| CN103203027A (zh) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schosserer et al. | Age-induced changes in white, brite, and brown adipose depots: a mini-review | |
| Lahiji et al. | Transcutaneous implantation of valproic acid-encapsulated dissolving microneedles induces hair regrowth | |
| US20200197488A1 (en) | Compositions and methods for treating hair loss | |
| Kimura-Ueki et al. | Hair cycle resting phase is regulated by cyclic epithelial FGF18 signaling | |
| JP5360593B2 (ja) | 発毛促進剤 | |
| US20180325940A1 (en) | Composition for preventing or ameliorating loss of hair and graying of hair, and use thereof | |
| JP6484174B2 (ja) | 皮膚老化を予防及び／又は改善するためのｐｅｄｆ−由来ポリペプチドの使用 | |
| US20220313658A1 (en) | YAP Inhibition for Wound Healing | |
| TWI614031B (zh) | 防止皮膚老化相關症狀的醫藥組合物及其使用方法 | |
| EP2873727A1 (en) | Brown fat cells and method for preparing same | |
| CN104602763B (zh) | 用于调节毛发生长的组合物和方法 | |
| CN113874044B (zh) | 皮肤组合物 | |
| TW201304816A (zh) | 皮膚之動力蛋白之調節 | |
| Hsu et al. | Nitric oxide produced by iNOS is associated with collagen synthesis in keloid scar formation | |
| WO2009065141A1 (en) | Methods and compositions for reducing skin damage | |
| Weber et al. | Activation of Pax7-positive cells in a non-contractile tissue contributes to regeneration of myogenic tissues in the electric fish S. macrurus | |
| US20120251455A1 (en) | Hair Growth-Inhibiting Agent | |
| CN105457015A (zh) | 重组creg蛋白抑制高血压血管重塑的医药用途 | |
| Hajem et al. | The regulatory role of the tetrapeptide A c SDKP in skin and hair physiology and the prevention of ageing effects in these tissues–a potential cosmetic role | |
| JP7312993B2 (ja) | エラスチン産生促進剤及び皮膚化粧料 | |
| JP6469767B2 (ja) | 皮膚老化を予防及び／又は改善するためのｐｅｄｆ−由来ポリペプチドの使用 | |
| JP6324597B1 (ja) | メラニン産生抑制剤、美白剤、遺伝子発現抑制剤、メラニン産生抑制用化粧料組成物及び美白用化粧料組成物 | |
| JP5847090B2 (ja) | 皮膚のバリア機能を改善するためのｃｅｒｔの発現を刺激する活性薬剤をスクリーニングするための方法 | |
| CN113929750B (zh) | 一种具有修复皮肤屏障功能的多肽及其应用 | |
| Diao et al. | Melatonin regulates the mitogen-activated protein kinase (MAPK) pathway via the circMPP5-miR-211-MAPK3 axis to induce secondary hair follicle differentiation and development in newborn Cashmere goat kids |